The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.
Cyrille Touzeau
No relevant relationships to disclose
Brigitte Kolb
No relevant relationships to disclose
Cyrille Hulin
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Denis Caillot
No relevant relationships to disclose
Lotfi Benboubker
No relevant relationships to disclose
Mourad Tiab
No relevant relationships to disclose
Xavier Leleu
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Murielle Roussel
Honoraria - Celgene; Janssen
Carine Chaleteix
No relevant relationships to disclose
Michel Attal
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen-Ortho
Thierry Facon
Consultant or Advisory Role - Celgene; Janssen; Millennium; Onyx
Honoraria - Celgene; Janssen
Philippe Moreau
Consultant or Advisory Role - Celgene; Janssen; Millennium; Onyx
Honoraria - Celgene; Janssen